Q-PAROXETINE DIN 02338807
Status: Cancelled Post Market
Holder: QD PHARMACEUTICALS ULC
Health Canada record
| Active ingredient(s) | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 20 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AB05 PAROXETINE |
| Original market date | 24-Nov-2011 |
| Current status date | 21-Aug-2015 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02248014 | MYLAN-PAROXETINE | MYLAN PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 30 MG | Cancelled Post Market |
| 02248012 | MYLAN-PAROXETINE | MYLAN PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 10 MG | Cancelled Post Market |
| 02248013 | MYLAN-PAROXETINE | MYLAN PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 20 MG | Cancelled Post Market |
| 02338793 | Q-PAROXETINE | QD PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 10 MG | Cancelled Post Market |
| 02338815 | Q-PAROXETINE | QD PHARMACEUTICALS ULC | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 30 MG | Cancelled Post Market |
| 02254751 | SANDOZ PAROXETINE | SANDOZ CANADA INCORPORATED | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 20 MG | Cancelled Post Market |
| 02254778 | SANDOZ PAROXETINE | SANDOZ CANADA INCORPORATED | Tablet | PAROXETINE (PAROXETINE HYDROCHLORIDE, ISOPROPYL SOLVATE) 30 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 12760 | 2011-11-04 | Abbreviated New Drug Submission (ANDS) | Manufacturer Name Change |
| 10850 | 2009-12-10 | Abbreviated New Drug Submission (ANDS) | Additional product name |